drugset / Trial / NCT00914303

Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241

NCT00914303

Phase 1 Completed 77 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindBasic science

Summary

The aims of the study are to assess the safety, tolerability and pharmacokinetics of ER tablets of AZD3241 following multiple ascending doses administered to healthy male and female subjects including the effect of food.

Timeline

Start
2009-06
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Verdiperstat Small molecule Oral

Indications

No indication recorded.